Related Articles
LEVELS OF P53 ANTIGEN IN THE SERUM OF NONSMALL CELL LUNG-CANCER PATIENTS CORRELATE WITH POSITIVE P53 IMMUNOHISTOCHEMISTRY ON TUMOR SECTIONS, TUMOR NECROSIS AND NODAL INVOLVEMENT
IMMUNOLOGICALLY DEFINED SUBCLASSES OF THE GROWTH SUPPRESSOR PROTEIN P53 DETECTED WITH ANTIBODIES IN SERA FROM TUMOR PATIENTS
Physical interaction between p53 and primary response gene Egr-1
miR‑19 in blood plasma reflects lung cancer occurrence but is not specifically associated with radon exposure
Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer